Fig. 5.

Achievement of ≤1 tender joint, patient assessment of pain VAS ≤15, HAQ-DI score ≤0.5, and PtGA ≤20

(A) ≤1 tender joint; (B) VAS ≤15; (C) HAQ-DI ≤0.5; (D) PtGA ≤20. Through week 24, patients meeting treatment failure criteria or with missing data were considered non-responders. Treatment group comparisons through week 24 were not adjusted for multiplicity of testing. After week 24 and through week 52, patients with missing data were considered non-responders. *P < 0.05, ⁺P < 0.01, ^‡P < 0.001, vs PBO (nominal). GUS: guselkumab; HAQ-DI: HAQ-Disability Index; PBO: placebo; PtGA: patient global assessment of disease activity (arthritis and psoriasis); Q4W: every 4 weeks; Q8W: every 8 weeks; VAS: visual analogue scale.